Technical Analysis for SVRA - Savara, Inc.

Grade Last Price % Change Price Change
C 1.83 -2.14% -0.04
SVRA closed down 2.14 percent on Friday, June 11, 2021, on 35 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Flat
Historical SVRA trend table...

Date Alert Name Type % Chg
Bollinger Band Squeeze Range Contraction 0.00%
BB Squeeze Started Range Contraction 0.00%
Overbought Stochastic Strength 0.00%
50 DMA Support Bullish -2.14%
180 Bullish Setup Bullish Swing Setup -2.14%
NR7 Range Contraction -2.14%
Overbought Stochastic Strength -2.14%
Shooting Star Candlestick Bearish 0.55%
Stochastic Sell Signal Bearish 0.55%
Lizard Bearish Bearish Day Trade Setup 0.55%
Older End-of-Day Signals for SVRA ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
10 DMA Support 3 days ago
60 Minute Opening Range Breakdown 3 days ago
Possible NR7 3 days ago
Down 2 % 3 days ago
Down 1% 3 days ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Savara, Inc. Description

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Pharmaceutical Clinical Development Heart Failure Stage Pharmaceutical Cystic Fibrosis Respiratory Disease Respiratory Diseases Staphylococcus Aureus Heart Diseases Treatment Of Heart Failure Lung Infection Diastolic Heart Failure Methicillin

Is SVRA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 3.58
52 Week Low 0.9952
Average Volume 1,733,116
200-Day Moving Average 1.52
50-Day Moving Average 1.81
20-Day Moving Average 1.74
10-Day Moving Average 1.82
Average True Range 0.11
ADX 19.55
+DI 19.88
-DI 12.51
Chandelier Exit (Long, 3 ATRs) 1.57
Chandelier Exit (Short, 3 ATRs) 1.80
Upper Bollinger Bands 1.93
Lower Bollinger Band 1.55
Percent B (%b) 0.73
BandWidth 21.88
MACD Line 0.03
MACD Signal Line 0.01
MACD Histogram 0.0171
Fundamentals Value
Market Cap 99.08 Million
Num Shares 54.1 Million
EPS -1.58
Price-to-Earnings (P/E) Ratio -1.16
Price-to-Sales 275.49
Price-to-Book 0.90
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.94
Resistance 3 (R3) 1.94 1.91 1.92
Resistance 2 (R2) 1.91 1.88 1.91 1.91
Resistance 1 (R1) 1.87 1.87 1.86 1.87 1.91
Pivot Point 1.84 1.84 1.83 1.84 1.84
Support 1 (S1) 1.80 1.81 1.79 1.80 1.75
Support 2 (S2) 1.77 1.80 1.77 1.75
Support 3 (S3) 1.73 1.77 1.74
Support 4 (S4) 1.73